Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol-Reference-Cited by-同舟云学术

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Published:2002-03 Issue:9311 Volume:359 Page:995-1003
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Dahlöf Björn,Devereux Richard B,Kjeldsen Sverre E,Julius Stevo,Beevers Gareth,de Faire Ulf,Fyhrquist Frej,Ibsen Hans,Kristiansson Krister,Lederballe-Pedersen Ole,Lindholm Lars H,Nieminen Markku S,Omvik Per,Oparil Suzanne,Wedel Hans

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration;Neal;Lancet,2000

2. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods;Dhlöf;Am J Hypertens,1997

3. Reduction of cardiovascular risk by regression of ectrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril;Mathew;Circulation,2001

4. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease;Brunner;Am J Cardiol,2001

5. Reversal of left ventricular hypertrophy in hypertensive patients – a meta-analysis of 109 treatment studies;Dahlöf;Am J Hypertens,1992

Cited by 4444 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Le concept de race : serpent de mer de la pratique médicale;Médecine & Droit;2024-09

2. The Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction "Twindemic” - Shared Root Causes and Treatment Targets;Heart Rhythm;2024-09

3. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors in Acute Myocardial Infarction Without Heart Failure;The American Journal of Medicine;2024-08

4. Sex-based differences in left ventricular mass reduction across angiotensin II receptor blockers in patients with heart failure with preserved or mildly reduced ejection fraction;Heart and Vessels;2024-07-30

5. Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions;Biomedicines;2024-07-26